down arrow

Xtant Medical Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98420P3082
USD
0.61
0.01 (2.09%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.610.65

52 Week

0.330.95
Valuation
Technical
Day's Volume

CASH

14.06 k

Shareholding (Mar 2025)

FII

0.10%

Held by 8 FIIs

DII

45.16%

Held by 12 DIIs

Promoter

52.60%

How big is Xtant Medical Holdings, Inc.?

22-Jun-2025

As of Jun 18, Xtant Medical Holdings, Inc. has a market capitalization of 83.61 million, with net sales of 122.29 million and a net profit of -11.99 million over the latest four quarters. The company reported shareholder's funds of 42.96 million and total assets of 93.84 million as of Dec 24.

Market Cap: As of Jun 18, Xtant Medical Holdings, Inc. has a market capitalization of 83.61 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Xtant Medical Holdings, Inc. reported net sales of 122.29 million and a net profit of -11.99 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 42.96 million and total assets of 93.84 million.

Read More

What does Xtant Medical Holdings, Inc. do?

22-Jun-2025

Xtant Medical Holdings, Inc. develops and markets regenerative medicine products and medical devices in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $33 million and has a market cap of $83.61 million.

Overview: <BR>Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 33 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 83.61 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 0.65 <BR>Return on Equity: -27.33% <BR>Price to Book: 1.91<BR><BR>Contact Details: <BR>Address: 664 Cruiser Ln, BELGRADE MT: 59714-9719 <BR>Tel: ['1 406 3880480', '1 877 8891972'] <BR>Fax: 1 302 6365454 <BR>Website: https://xtantmedical.com/

Read More

Who are in the management team of Xtant Medical Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Xtant Medical Holdings, Inc. includes Sean Browne (President and CEO), John Bakewell, Michael Eggenberg, Robert McNamara, Jeffrey Peters, and Matthew Rizzo, all serving as directors. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Xtant Medical Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Sean Browne: President, Chief Executive Officer, and Director<BR>- Mr. John Bakewell: Director<BR>- Mr. Michael Eggenberg: Director<BR>- Mr. Robert McNamara: Director<BR>- Mr. Jeffrey Peters: Director<BR>- Mr. Matthew Rizzo: Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is Xtant Medical Holdings, Inc. overvalued or undervalued?

20-Sep-2025

As of May 15, 2024, Xtant Medical Holdings, Inc. is considered a risky investment due to its overvaluation, negative performance metrics, and significant inefficiencies in generating returns, despite a year-to-date stock performance that has outpaced the S&P 500.

As of 15 May 2024, the valuation grade for Xtant Medical Holdings, Inc. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 2.21 and an EV to Sales ratio of 1.03, which suggest that investors are paying a premium despite the company’s losses. Additionally, the ROE stands at -27.33%, highlighting significant inefficiencies in generating returns for shareholders.<BR><BR>In comparison to its peers, Xtant Medical's EV to EBITDA ratio of -38.64 is notably worse than Bioventus, Inc., which has a more favorable EV to EBITDA of 9.72, and Axogen, Inc., which shows a significantly negative P/E of -146.35. The stock has outperformed the S&P 500 with a year-to-date return of 48.98% compared to the index's 12.22%, but this short-term performance does not mitigate the overall valuation concerns.

Read More

Is Xtant Medical Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Xtant Medical Holdings, Inc. shows a mildly bullish trend driven by daily moving averages, despite mixed signals from weekly indicators and underperformance over longer periods, while year-to-date it has outperformed the S&P 500 with a return of 48.98%.

As of 12 September 2025, the technical trend for Xtant Medical Holdings, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands show a bullish trend on the weekly but a mildly bearish trend on the monthly. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the monthly MACD.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 48.98% compared to the S&P 500's 12.22%. However, over longer periods, such as 3 years and 5 years, the stock has underperformed significantly against the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 80 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.58

stock-summary
Return on Equity

-9.45%

stock-summary
Price to Book

1.65

Revenue and Profits:
Net Sales:
35 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.03%
0%
0.03%
6 Months
-10.51%
0%
-10.51%
1 Year
51.97%
0%
51.97%
2 Years
-53.41%
0%
-53.41%
3 Years
1.97%
0%
1.97%
4 Years
-13.27%
0%
-13.27%
5 Years
-52.69%
0%
-52.69%

Xtant Medical Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Xtant Medical Holdings, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Xtant Medical Holdings, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands show a bullish trend on the weekly but a mildly bearish trend on the monthly. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the monthly MACD. In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 48.98% compared to the S&P 500's 12.22%. However, over longer periods, such as 3 years and 5 years, the stock has underperformed significantly against the benchmark....

Read More

Is Xtant Medical Holdings, Inc. overvalued or undervalued?

As of 15 May 2024, the valuation grade for Xtant Medical Holdings, Inc. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 2.21 and an EV to Sales ratio of 1.03, which suggest that investors are paying a premium despite the company’s losses. Additionally, the ROE stands at -27.33%, highlighting significant inefficiencies in generating returns for shareholders. In comparison to its peers, Xtant Medical's EV to EBITDA ratio of -38.64 is notably worse than Bioventus, Inc., which has a more favorable EV to EBITDA of 9.72, and Axogen, Inc., which shows a significantly negative P/E of -146.35. The stock has outperformed the S&P 500 with a year-to-date return of 48.98% compared to the index's 12.22%, but this short-term performance does not mitigate the overall valuation ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.12%
EBIT Growth (5y)
14.99%
EBIT to Interest (avg)
-2.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.65
Sales to Capital Employed (avg)
1.34
Tax Ratio
0.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
70.95%
ROCE (avg)
0.38%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.21
EV to EBIT
-16.64
EV to EBITDA
-38.64
EV to Capital Employed
1.73
EV to Sales
1.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.39%
ROE (Latest)
-27.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (2.14%)

Foreign Institutions

Held by 8 Foreign Institutions (0.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.60% vs 4.44% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3,400.00% vs 103.12% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.40",
          "val2": "32.90",
          "chgp": "7.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.80",
          "val2": "2.10",
          "chgp": "176.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.50",
          "val2": "0.10",
          "chgp": "3,400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "130.60%",
          "val2": "32.30%",
          "chgp": "9.83%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 28.48% vs 57.41% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2,442.86% vs 108.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "117.30",
          "val2": "91.30",
          "chgp": "28.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-7.00",
          "chgp": "-12.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.20",
          "val2": "2.90",
          "chgp": "44.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.40",
          "val2": "0.70",
          "chgp": "-2,442.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-103.00%",
          "val2": "-111.30%",
          "chgp": "0.83%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
35.40
32.90
7.60%
Operating Profit (PBDIT) excl Other Income
5.80
2.10
176.19%
Interest
1.00
1.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.50
0.10
3,400.00%
Operating Profit Margin (Excl OI)
130.60%
32.30%
9.83%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 7.60% vs 4.44% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 3,400.00% vs 103.12% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
117.30
91.30
28.48%
Operating Profit (PBDIT) excl Other Income
-7.90
-7.00
-12.86%
Interest
4.20
2.90
44.83%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-16.40
0.70
-2,442.86%
Operating Profit Margin (Excl OI)
-103.00%
-111.30%
0.83%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 28.48% vs 57.41% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2,442.86% vs 108.24% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Xtant Medical Holdings, Inc. stock-summary
stock-summary
Xtant Medical Holdings, Inc.
Pharmaceuticals & Biotechnology
Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.
Company Coordinates stock-summary
Company Details
664 Cruiser Ln , BELGRADE MT : 59714-9719
stock-summary
Tel: 1 406 38804801 877 8891972
stock-summary
https://xtantmedical.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."